Literature DB >> 3934694

The effects of L-threo-dihydroxyphenylserine on norepinephrine metabolism in rat brain.

J Semba, R Takahashi.   

Abstract

The effects of L-threo-3,4-dihydroxyphenylserine (DOPS), an artificial precursor of norepinephrine (NE), on NE metabolism in rat brain were investigated. DOPS administration resulted in a significant elevation in cerebral NE and 3-methoxy-4-hydroxyphenylglycol contents, while carbidopa pretreatment completely blocked these increases. After brain NE was depleted by either alpha-methyl-p-tyrosine (AMPT), fusaric acid, FLA-63, or reserpine, NE restoration by DOPS was observed in rats treated with either fusaric acid or chronic reserpine. No NE restoration was observed after pretreatment with AMPT, FLA-63, or acute reserpine. The results suggest that NE formed after DOPS administration is mainly localized in the brain capillaries. In some NE-depleting conditions, however, DOPS can penetrate the brain parenchyma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3934694     DOI: 10.1016/0165-1781(85)90069-1

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  3 in total

1.  Neurocognitive function in dopamine-β-hydroxylase deficiency.

Authors:  Marieke Jepma; Jaap Deinum; Christopher L Asplund; Serge Arb Rombouts; Jouke T Tamsma; Nathanja Tjeerdema; Michiel M Spapé; Emily M Garland; David Robertson; Jacques Wm Lenders; Sander Nieuwenhuis
Journal:  Neuropsychopharmacology       Date:  2011-04-06       Impact factor: 7.853

2.  Memory effect of DL-threo-3,4-dihydroxyphenylserine (DOPS) in human Korsakoff's disease.

Authors:  P J Langlais; R G Mair; P J Whalen; W McCourt; W J McEntee
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

3.  The noradrenaline precursor L-threo-3,4-dihydroxyphenylserine exhibits antinociceptive activity via central alpha-adrenoceptors in the mouse.

Authors:  A Kawabata; K Kasamatsu; N Umeda; H Takagi
Journal:  Br J Pharmacol       Date:  1994-02       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.